Occipital Neuralgia |
|
|
Clinical Trial: Pregabalin Peripheral Neuropathic Pain Study
This study is not yet open for patient recruitment.
Verified by Pfizer August 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Diabetic Diabetic Neuropathies Neuralgia | Drug: Administration | Phase III |
MedlinePlus related topics: Pain; Peripheral Nerve Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pregabalin (150 Mg - 600 Mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects with Peripheral Neuropathic Pain
Secondary Outcomes: •Proportion of 30% Responders (With Respect to Pain Scores) at Endpoint.; •Proportion of 50% Responders (With Respect to Pain Scores) at Endpoint.; •Weekly Mean Pain Score from DPRS.; •Weekly Mean Sleep Interference Score from Daily Sleep Interference Scale
Expected Total Enrollment: 234
Study start: August 2005
Eligibility
Inclusion Criteria:
- Diagnosis of peripheral neuropathic pain syndrome, including DPN, PHN, or post-traumatic neuropathic pain (including post-surgical), confirmed by a qualified pain specialist.
- Subjects must have completed at least 4 daily pain diaries during the 7 days prior to Visit 2 and have an average pain score of > 4 over the 7 days prior to Visit 2 (randomization).
Exclusion Criteria:
- Neurologic disorders unrelated to DPN, PHN, or post-traumatic neuropathic pain (including post-surgical), that may confuse or confound the assessment of neuropathic pain.
- Presence of any severe pain associated with conditions other than DPN, PHN, or post-traumatic neuropathic pain (including post-surgical) that may confound the assessment or self evaluation of the pain due to DPN, PHN, or post-traumatic neuropathic pain (including post-surgical).
Location and Contact Information
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Last Updated: August 31, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00141219
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)
ClinicalTrials.gov processed this record on 2005-09-06

Not Signed In -


